even after multiple chemotherapy lines, platinum sensitivity is associate with a longer therapy-free interval. The aim of this study was to investigate platinum resistance in long-term OvCa survivors. Methodology Patients diagnosed with OvCa at the Tuebingen University Women's Hospital between 2000 and 2012 were retrospectively identified and follow-up data was collected. For patients surviving at least 8 years a detailed chart review was performed. Platinum resistance was defined as disease progression during platinum-based chemotherapy or 6 months after the last platinum dose administration. Result(s)* From a total n=745 of patients with adequate follow-up data, n=223(30%) survived at least 8 years after primary diagnosis. Median follow-up was 12.1 years and median age at diagnosis was 54.7 years. Relapse was recorded in 87/ 223(39%) patients, of which 28/87(32%) developed platinum resistance at some point. Platinum resistance was observed after the second line chemotherapy in most patients (median: 2, range: 1-4). 23/28 patients received further chemotherapy lines (median: 2, range: 0-8). Rechallenge with a platinumbased chemotherapy has been used in 9/28(32%) patients. Median overall survival of these 28 patients was 9.3 years (8.2-18.4, IQR3.7) and 4.1 (0.4-16.8, IQR3.8) years after platinum resistance. Conclusion* We were able to demonstrate long-term survival after platinum resistance in a substantial number of ovarian carcinoma patients. Suggesting therefore, that other parameters influence the disease behaviour. Further research of patient characteristics, environmental and genetic features and treatment modalities will help to further understand factors contributing to long-term survival.

No abstract

controlling for patient age, diagnosis year, race/ethnicity, stage, grade, number of positive regional lymph nodes, and tumor size.Results A total of 2,362 patients were identified. A significant improvement in cause specific survival (CSS) was noted in patients who underwent combination therapy (vaginal brachytherapy [VB] plus external beam radiation therapy [EBRT]) versus chemotherapy alone (hazard ratio [HR] 0.805, 95% confidence interval [CI] 0.674-0.961, p<0.05). VB and EBRT each given exclusively versus chemotherapy alone resulted in improved overall survival (OS) ([VB HR 0.852, 95% CI 0.788-0.920, p<0.001], [EBRT HR 0.758, 95% CI 0.646-0.889, p=0.001]), but not cause specific survival (CSS). No difference in survival was found in VB or EBRT alone versus combination therapy, or in EBRT versus VB. Conclusions Combination aRT with chemotherapy shows superior CSS compared to chemotherapy alone. This SEER database study validates aRT use in this rare subset of high-risk endometrial cancer.